- Home
- HROW vs OMCL Comparison
HROW vs OMCL Comparison
Compare HROW & OMCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HROW
- OMCL
- Stock Information
- Founded
- HROW 1998
- OMCL 1992
- Country
- HROW United States
- OMCL United States
- Employees
- HROW N/A
- OMCL N/A
- Industry
- HROW Biotechnology: Pharmaceutical Preparations
- OMCL Computer Manufacturing
- Sector
- HROW Health Care
- OMCL Technology
- Exchange
- HROW Nasdaq
- OMCL Nasdaq
- Market Cap
- HROW 1.4B
- OMCL 1.5B
- IPO Year
- HROW N/A
- OMCL 2001
- Fundamental
- Price
- HROW $43.15
- OMCL $31.18
- Analyst Decision
- HROW Strong Buy
- OMCL Buy
- Analyst Count
- HROW 7
- OMCL 7
- Target Price
- HROW $64.67
- OMCL $46.71
- AVG Volume (30 Days)
- HROW 506.9K
- OMCL 470.2K
- Earning Date
- HROW 11-12-2025
- OMCL 10-29-2025
- Dividend Yield
- HROW N/A
- OMCL N/A
- EPS Growth
- HROW N/A
- OMCL N/A
- EPS
- HROW N/A
- OMCL 0.49
- Revenue
- HROW $227,661,000.00
- OMCL $1,149,529,000.00
- Revenue This Year
- HROW $45.86
- OMCL $5.37
- Revenue Next Year
- HROW $41.41
- OMCL $3.67
- P/E Ratio
- HROW N/A
- OMCL $63.63
- Revenue Growth
- HROW 47.69
- OMCL 6.39
- 52 Week Low
- HROW $20.85
- OMCL $22.66
- 52 Week High
- HROW $59.23
- OMCL $55.75
- Technical
- Relative Strength Index (RSI)
- HROW 69.90
- OMCL 45.32
- Support Level
- HROW $38.47
- OMCL $31.73
- Resistance Level
- HROW $44.07
- OMCL $33.32
- Average True Range (ATR)
- HROW 1.71
- OMCL 0.97
- MACD
- HROW 0.38
- OMCL -0.23
- Stochastic Oscillator
- HROW 89.11
- OMCL 0.44
About HROW Harrow Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
About OMCL Omnicell Inc. ($0.001 par value)
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.